|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 76.91 USD | +4.00% |
|
+7.88% | -1.16% |
| 06-09 | Kymera Therapeutics Unlocks $20 Million Milestone After Dosing First Participant in KT-485 Phase 1 Trial | MT |
| 06-08 | Kymera Therapeutics, Inc. Announces Executive Changes | CI |
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
Assets | ||||||||
Cash And Equivalents | 47.98M | 68.4M | 110M | 120M | 357M | |||
Short Term Investments | 394M | 339M | 265M | 368M | 491M | |||
Total Cash And Short Term Investments | 442M | 407M | 375M | 489M | 848M | |||
Accounts Receivable, Total | 135K | 2.54M | 18.76M | 947K | - | |||
Other Receivables | - | - | - | - | - | |||
Total Receivables | 135K | 2.54M | 18.76M | 947K | - | |||
Prepaid Expenses | 8.72M | 9.71M | 11.67M | 20.58M | 22.94M | |||
Total Current Assets | 451M | 419M | 405M | 510M | 871M | |||
Gross Property Plant And Equipment | 25.22M | 29.14M | 112M | 114M | 108M | |||
Accumulated Depreciation | -3.92M | -6.89M | -10.44M | -16.07M | -22.13M | |||
Net Property Plant And Equipment | 21.31M | 22.24M | 101M | 97.86M | 85.53M | |||
Long-term Investments | 125M | 152M | 61.43M | 362M | 771M | |||
Other Long-Term Assets, Total | 8.14M | 9.15M | 7.93M | 7.74M | 14.91M | |||
Total Assets | 606M | 603M | 576M | 978M | 1.74B | |||
Liabilities | ||||||||
Accounts Payable, Total | 4M | 4.34M | 7.08M | 5.99M | 4.02M | |||
Accrued Expenses, Total | 22.97M | 27.5M | 33.86M | 34.87M | 42.27M | |||
Current Portion of Leases | 3.6M | 3.94M | 6.34M | 13.11M | 13.76M | |||
Unearned Revenue Current, Total | 61.74M | 35.26M | 37.88M | 13.58M | 22.92M | |||
Other Current Liabilities | 228K | 303K | 524K | 223K | 242K | |||
Total Current Liabilities | 92.54M | 71.34M | 85.69M | 67.77M | 83.21M | |||
Long-Term Leases | 14.36M | 13.39M | 78.33M | 74.65M | 68.5M | |||
Unearned Revenue Non Current | 39.3M | 28M | 16.77M | - | 11.44M | |||
Other Non Current Liabilities | 66K | 248K | - | - | - | |||
Total Liabilities | 146M | 113M | 181M | 142M | 163M | |||
Preferred Stock Convertible | - | - | - | - | - | |||
Total Preferred Equity | - | - | - | - | - | |||
Common Stock, Total | 5K | 6K | 6K | 7K | 8K | |||
Additional Paid In Capital | 689M | 879M | 926M | 1.59B | 2.64B | |||
Retained Earnings | -229M | -384M | -531M | -755M | -1.07B | |||
Comprehensive Income and Other | -660K | -4.95M | -552K | -1.48M | 1.8M | |||
Total Common Equity | 460M | 490M | 395M | 836M | 1.58B | |||
Total Equity | 460M | 490M | 395M | 836M | 1.58B | |||
Total Liabilities And Equity | 606M | 603M | 576M | 978M | 1.74B | |||
Supplemental Items | ||||||||
ECS Total Shares Outstanding on Filing Date | 51.67M | 55.18M | 61.11M | 64.94M | 81.64M | |||
ECS Total Common Shares Outstanding | 51.5M | 55.04M | 55.59M | 64.89M | 81.32M | |||
Book Value / Share | 8.93 | 8.91 | 7.11 | 12.88 | 19.42 | |||
Tangible Book Value | 460M | 490M | 395M | 836M | 1.58B | |||
Tangible Book Value Per Share | 8.93 | 8.91 | 7.11 | 12.88 | 19.42 | |||
Total Debt | 17.96M | 17.34M | 84.67M | 87.76M | 82.25M | |||
Net Debt | -550M | -542M | -352M | -763M | -1.54B | |||
Debt Equivalent Oper. Leases | 24.88M | 26.3M | 86.94M | 120M | 127M | |||
Account Code - Inventory Valuation | 3 | 3 | 3 | 3 | 3 | |||
Machinery, Total | 4.02M | 5.8M | 6.74M | 14.75M | 15.77M | |||
Full Time Employees | 141 | 167 | 187 | 188 | 238 | |||
Assets under Capital Lease - Gross | - | - | - | - | - | |||
Assets under Capital Lease - Accumulated Depreciation | - | - | - | - | - |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















